QIAGEN(QGEN) - 2023 Q4 - Earnings Call Presentation

Forward looking and intended use statements Q4: $503 million CER(1) vs outlook of ≥ $500 m CER 2023 adjusted diluted EPS Adj. EPS: ≥ $2.10 CER • QuantiFERON: +24% CER FY sales, annual sales milestone of >$400m Strong profitability profile supports capital deployment • Closely monitoring macro-economic and customer demand trends Q4 2023: +8% CER growth from non-COVID product groups Growth rates vs. Q4 2022. | Refer to appendix for product group growth at actual rates. | Tables may contain rounding difference ...